BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 31259656)

  • 1. The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma.
    Oon ML; Hoppe MM; Fan S; Phyu T; Phuong HM; Tan SY; Hue SS; Wang S; Poon LM; Chan HLE; Lee J; Chee YL; Chng WJ; de Mel S; Liu X; Jeyasekharan AD; Ng SB
    Leuk Lymphoma; 2019 Dec; 60(13):3214-3224. PubMed ID: 31259656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of expressions of PDK1, PLK1 and c-Myc in diffuse large B-cell lymphoma.
    Feng Y; Lin J; Liu Y; Tang Y; Zhou Y; Zhong M
    Int J Exp Pathol; 2019 Feb; 100(1):32-40. PubMed ID: 30912195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.
    Ren Y; Bi C; Zhao X; Lwin T; Wang C; Yuan J; Silva AS; Shah BD; Fang B; Li T; Koomen JM; Jiang H; Chavez JC; Pham LV; Sudalagunta PR; Wan L; Wang X; Dalton WS; Moscinski LC; Shain KH; Vose J; Cleveland JL; Sotomayor EM; Fu K; Tao J
    J Clin Invest; 2018 Dec; 128(12):5517-5530. PubMed ID: 30260324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma.
    Imai H; Sugimoto K; Isobe Y; Sasaki M; Yasuda H; Takeuchi K; Nakamura S; Kojima Y; Tomomatsu J; Oshimi K
    Int J Hematol; 2009 Jun; 89(5):673-8. PubMed ID: 19452252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
    Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
    Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases.
    Agarwal R; Lade S; Liew D; Rogers TM; Byrne D; Feleppa F; Juneja S; Westerman DA
    J Clin Pathol; 2016 Mar; 69(3):266-70. PubMed ID: 26307073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
    Mationg-Kalaw E; Tan LH; Tay K; Lim ST; Tang T; Lee YY; Tan SY
    Histopathology; 2012 Dec; 61(6):1214-8. PubMed ID: 23171357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of PLK1 and survivin in diffuse large B-cell lymphoma.
    Liu L; Zhang M; Zou P
    Leuk Lymphoma; 2007 Nov; 48(11):2179-83. PubMed ID: 17943598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of the spindle checkpoint protein BubR1 is associated with high cell proliferation in primary gastrointestinal diffuse large B cell lymphoma.
    Chen F; Yang G; Xia B
    Cell Biochem Biophys; 2013 Jul; 66(3):747-52. PubMed ID: 23400934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of aurora A and polo-like kinases in high-risk lymphomas.
    Murga-Zamalloa C; Inamdar KV; Wilcox RA
    Blood Adv; 2019 Jun; 3(11):1778-1787. PubMed ID: 31186254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 12. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
    Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S
    Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma.
    Pătraşcu AM; Rotaru I; Olar L; Pătraşcu Ş; Ghiluşi MC; NeamŢu SD; Nacea JG; Gluhovschi A
    Rom J Morphol Embryol; 2017; 58(3):837-843. PubMed ID: 29250662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.
    Gong QX; Wang Z; Liu C; Li X; Lu TX; Liang JH; Xu W; Li JY; Zhang ZH
    J Clin Pathol; 2018 Sep; 71(9):795-801. PubMed ID: 29666157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.
    Cui W; Zheng S; Li X; Ma Y; Sang W; Liu M; Zhang W; Zhou X
    Tumour Biol; 2016 Sep; 37(9):12767-12777. PubMed ID: 27448819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.
    Abdulla M; Laszlo S; Triumf J; Hedström G; Berglund M; Enblad G; Amini RM
    Acta Oncol; 2016; 55(9-10):1126-1131. PubMed ID: 27549735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
    Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
    Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of Polo-like kinase 1 (Plk1) in quiescence regulation of cancer stem-like cells of the gastric cancer cell lines.
    Zhu L; Xing S; Zhang L; Yu JM; Lin C; Yang WJ
    Oncotarget; 2017 Jun; 8(23):37633-37645. PubMed ID: 28430578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
    Gualco G; Weiss LM; Barber GN; Bacchi CE
    Hum Pathol; 2010 Sep; 41(9):1238-44. PubMed ID: 20382409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.